A Phase 1 interventional study of VH4011499 and Ritonavir in HIV Infections, sponsored by ViiV Healthcare. Not yet recruiting. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 109th largest by planned enrollment of the 210 interventional ones that give a count, is one of 10 that started in 2026, is one of 83 in phase 1, reaches primary completion later than 14 of the 26 other live ones, and was the 266th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in Romania, South Africa, Uganda
ViiV Healthcare · Sites in Netherlands
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 85 · Phase 2 53 · Phase 3 68 · Phase 4 18
First in 1994; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is close to the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 82 across the 210 interventional studies, 328 across the 14 observational. Of the 230 that completed or were terminated, 95 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
6 of the studies in HIV Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07053384ViiV HealthcareA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | 2027-01-22 |
| NCT07934719ViiV HealthcareMass Balance and Absolute Bioavailability of [14C]-VH4011499 | 2027-02-18 |
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
| NCT07939594ViiV HealthcareAn Evaluation of the Potential for VH4011499 Drug-drug-interactions | 2027-03-12 |
| NCT07525544ViiV HealthcareA Study to Investigate the Safety and PK of VH4770359 in Healthy Participants | 2027-05-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 266 studies in HIV Infections by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the pharmacokinetic (PK) interactions between VH4011499 and representative drugs containing inhibitors and inducers, selected transporters, and statins, in HIV negative adults. The study will also assess to assess safety and tolerability during co-administration of VH4011499 with the selected drugs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female:
Male Participants:
No restrictions for male participants.
They are a woman of non-child bearing potential (WONCBP). There is no requirement for female study participants to use a highly effective method of since, to be eligible, they must be of nonchildbearing potential.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-54, participants receive Ritonavir twice daily. On Day 26, participants receive another single dose of VH4011499, along with Ritonavir.
Drug: VH4011499 · Drug: Ritonavir
Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-58, participants receive Efavirenz once daily. On Day 37, participants receive another single dose of VH4011499, along with Efavirenz.
Drug: VH4011499 · Drug: Efavirenz
Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-25, participants receive Carbamazepine low dose; on days 26-28, they receive Carbamazepine medium dose; and on days 29-62, they receive Carbamazepine high dose. On Day 41, the participants receive another single dose of VH4011499, along with Carbamazepine high dose.
Drug: VH4011499 · Drug: Carbamazepine
Participants receive a dose of Metformin and Digoxin on Day 1, followed by a 14-day washout period. On days 10-24, participants receive VH4011499 once daily (a higher dose on Day 10, followed by a lower dose on days 11-24). On Day 16, participants receive another dose of Metformin and Digoxin, along with VH4011499.
Drug: VH4011499 · Drug: Metformin · Drug: Digoxin
Participants receive a dose of Rosuvastatin on Day 1, and a dose of Pitavastatin on Day 5, followed by a 10-day washout period. On days 11-26, participants receive VH4011499 once daily (a higher dose on Day 11, followed by a lower dose on days 12-26). On Day 17, participants receive another dose of Pitavastatin, and on Day 22 they receive another dose of Rosuvastatin, along with VH4011499.
Drug: VH4011499 · Drug: Rosuvastatin · Drug: Pitavastatin
VH4011499 is administered to the participants based on the protocol schedule.
Ritonavir is administered to the participants based on the protocol schedule.
Efavirenz is administered to the participants based on the protocol schedule.
Carbamazepine is administered to the participants based on the protocol schedule.
Metformin is administered to the participants based on the protocol schedule.
Digoxin is administered to the participants based on the protocol schedule.
Rosuvastatin is administered to the participants based on the protocol schedule.
Pitavastatin is administered to the participants based on the protocol schedule.
Maximum plasma concentration (Cmax) of VH4011499 when administered alone
Time frame: Day 1 for Cohorts 1, 2 and 3
Cmax of VH4011499 when co-administered with Ritonavir
Time frame: Day 26
Cmax of VH4011499 when co-administered with Efavirenz
Time frame: Day 37
Cmax of VH4011499 when co-administered with Carbamazepine
Time frame: Day 41
Area under the concentration-time curve from 0 to tau [AUC(0-t)] of VH4011499 when administered alone
Time frame: Day 1 for Cohorts 1, 2 and 3
AUC(0-t) of VH4011499 when co-administered with Ritonavir
Time frame: Day 26
AUC(0-t) of VH4011499 when co-administered with Efavirenz
Time frame: Day 37
AUC(0-t) of VH4011499 when co-administered with Carbamazepine
Time frame: Day 41
Area under the concentration-time curve from 0 to infinity [AUC(0-inf)] of VH4011499 when administered alone
Time frame: Day 1 for Cohorts 1, 2 and 3
AUC(0-inf) of VH4011499 when co-administered with Ritonavir
Time frame: Day 26
AUC(0-inf) of VH4011499 when co-administered with Efavirenz
Time frame: Day 37
AUC(0-inf) of VH4011499 when co-administered with Carbamazepine
Time frame: Day 41
Cmax of Metformin when administered alone
Time frame: Day 1
Cmax of Metformin when co-administered with VH4011499
Time frame: Day 16
AUC(0-t) of Metformin when administered alone
Time frame: Day 1
AUC(0-t) of Metformin when co-administered with VH4011499
Time frame: Day 16
AUC(0-inf) of Metformin when administered alone
Time frame: Day 1
AUC(0-inf) of Metformin when co-administered with VH4011499
Time frame: Day 16
Cmax of Digoxin when administered alone
Time frame: Day 1
Cmax of Digoxin when co-administered with VH4011499
Time frame: Day 16
AUC(0-t) of Digoxin when administered alone
Time frame: Day 1
AUC(0-t) of Digoxin when co-administered with VH4011499
Time frame: Day 16
AUC(0-inf) of Digoxin when administered alone
Time frame: Day 1
AUC(0-inf) of Digoxin when co-administered with VH4011499
Time frame: Day 16
Cmax of Rosuvastatin when administered alone
Time frame: Day 5
Cmax of Rosuvastatin when co-administered with VH4011499
Time frame: Day 22
AUC(0-t) of Rosuvastatin when administered alone
Time frame: Day 5
AUC(0-t) of Rosuvastatin when co-administered with VH4011499
Time frame: Day 22
AUC(0-inf) of Rosuvastatin when administered alone
Time frame: Day 5
AUC(0-inf) of Rosuvastatin when co-administered with VH4011499
Time frame: Day 22
Cmax of Pitavastatin when administered alone
Time frame: Day 1
Cmax of Pitavastatin when co-administered with VH4011499
Time frame: Day 17
AUC(0-t) of Pitavastatin when administered alone
Time frame: Day 1
AUC(0-t) of Pitavastatin when co-administered with VH4011499
Time frame: Day 17
AUC(0-inf) of Pitavastatin when administered alone
Time frame: Day 1
AUC(0-inf) of Pitavastatin when co-administered with VH4011499
Time frame: Day 17
Number of participants with adverse events (AEs), overall and by grade.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The intensity of AEs is reported based on the Division of acquired immunodeficiency syndrome (DAIDS) grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death.
Time frame: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with AEs leading to study treatment discontinuation
Time frame: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with change from baseline in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
Time frame: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with maximum toxicity grade increase in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
The toxicity is reported based on DAIDS grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death.
Time frame: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Time to maximum plasma concentration (Tmax) of VH4011499 when administered alone.
Time frame: Day 1 for Cohorts 1, 2 and 3
Tmax of VH4011499 when co-administered with Ritonavir
Time frame: Day 26
Tmax of VH4011499 when co-administered with Efavirenz
Time frame: Day 37
Tmax of VH4011499 when co-administered with Carbamazepine
Time frame: Day 41
Apparent oral clearance (CL/F) of VH4011499 when administered alone
Time frame: Day 1 for Cohorts 1, 2 and 3
CL/F of VH4011499 when co-administered with Ritonavir
Time frame: Day 26
CL/F of VH4011499 when co-administered with Efavirenz
Time frame: Day 37
CL/F of VH4011499 when co-administered with Carbamazepine
Time frame: Day 41
Apparent terminal half-life (t1/2) of VH4011499 when administered alone
Time frame: Day 1 for Cohorts 1, 2 and 3
t1/2 of VH4011499 when co-administered with Ritonavir
Time frame: Day 26
t1/2 of VH4011499 when co-administered with Efavirenz
Time frame: Day 37
t1/2 of VH4011499 when co-administered with Carbamazepine
Time frame: Day 41
Cmax of VH4011499 when co-administered with Metformin and Digoxin
Time frame: Day 16
AUC(0-t) of VH4011499 when co-administered with Metformin and Digoxin
Time frame: Day 16
AUC(0-inf) of VH4011499 when co-administered with Metformin and Digoxin
Time frame: Day 16
Cmax of Ritonavir when co-administered with VH4011499
Time frame: Day 26
AUC(0-t) of Ritonavir when co-administered with VH4011499
Time frame: Day 26
AUC(0-inf) of Ritonavir when co-administered with VH4011499
Time frame: Day 26
Cmax of Efavirenz when co-administered with VH4011499
Time frame: Day 37
AUC(0-t) of Efavirenz when co-administered with VH4011499
Time frame: Day 37
AUC(0-inf) of Efavirenz when co-administered with VH4011499
Time frame: Day 37
Cmax of Carbamazepine when co-administered with VH4011499
Time frame: Day 41
AUC(0-t) of Carbamazepine when co-administered with VH4011499
Time frame: Day 41
AUC(0-inf) of Carbamazepine when co-administered with VH4011499
Time frame: Day 41
Cmax of VH4011499 when co-administered with Rosuvastatin
Time frame: Day 22
AUC(0-t) of VH4011499 when co-administered with Rosuvastatin
Time frame: Day 22
AUC(0-inf) of VH4011499 when co-administered with Rosuvastatin
Time frame: Day 22
Cmax of VH4011499 when co-administered with Pitavastatin
Time frame: Day 17
AUC(0-t) of VH4011499 when co-administered with Pitavastatin
Time frame: Day 17
AUC(0-inf) of VH4011499 when co-administered with Pitavastatin
Time frame: Day 17
No study locations are listed for this record.
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.viiv-studyregister.com
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2027, 3 months later.
Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's planned 3 months is below that.
Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dezecapavir